Pharmafile Logo
Pharmafocus logo
Advanced Search

Roche and Eli Lilly collaborate on Alzheimer’s disease blood test

March 22, 2023
Medical Communications

Swiss biotech company Roche has announced a collaboration with US pharmaceutical company Eli Lilly to develop Roche’s Elecsys Amyloid Plasma …

News

Kite’s Yescarta CAR T-cell therapy shows statistically significant improvement in overall survival

March 22, 2023
Research and Development

Kite has announced the primary overall survival (OS) analysis results of a phase 3 study into Yescarta for the treatment …

News

Promising ovarian cancer drug enters phase 3 trial

March 22, 2023

A new drug to treat ovarian cancer is set to enter the phase 3 UP-NEXT trial imminently.  Upifitamab rilsodotin is …

News

Faron Pharmaceuticals announces positive FDA feedback for solid tumour therapy

March 22, 2023
Research and Development

Faron Pharmaceuticals, a clinical stage biopharmaceutical company, has revealed positive FDA feedback and recommendations for its monotherapy for solid tumour …

News

Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions

March 21, 2023
Business Services

OXFORD, United Kingdom, March 20, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company focused on the …

News
Press release

BioNTech and OncoC4 to partner for development and commercialisation of novel checkpoint antibody

March 21, 2023
Sales and Marketing

BioNTech and OncoC4 have entered a strategic collaboration for the co-development and commercialisation of a novel checkpoint antibody for multiple …

News

First candidate from Nurix-Gilead Sciences collaboration exclusively licensed

March 21, 2023
Research and Development

US-based Gilead Sciences and Nurix have announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein …

News

FDA staff appear to support Biogen’s ALS drug despite limited data

March 21, 2023
Medical Communications

It appears that the FDA is inclined to support Biogen’s amyotrophic lateral sclerosis (ALS) drug, tofersen, with documents released on …

News

FDA approves Surgvision’s Explorer Air II device

March 21, 2023
Medical Communications

Medical technology company Surgvision has announced that it has received FDA 510(k) approval for its Explorer Air II device. It …

News

Mobiquity Report Reveals Top Mobile Health App Features that help to increase patient engagement.

March 20, 2023
Business Services

Mobiquity, a digital consultancy that designs and delivers innovative digital products and services for the world’s leading brands, released today …

News
Press release

AbbVie shares results from study for new psoriasis therapy

March 20, 2023
Research and Development

AbbVie has announced new 52-week data from a study assessing the efficacy of new IL-23 inhibitor, Skyrizi (risankizumab). Patients with …

News

QurAlis Corporation announces programme which targets UNC13A mis-splicing in neurodegenerative diseases

March 20, 2023
Research and Development

US-based clinical-stage biotechnology QurAlis Corporation has announced the launch of its newest programme to treat neurodegenerative diseases like ALS and …

News

AstraZeneca and MSD announce MHRA marketing authorisation of Lynparza combination therapy

March 20, 2023
Medical Communications

AstraZeneca and MSD have announced that the MHRA has granted marketing authorisation for Lynparza (olaparib) in the UK, when used …

News

Oxford Nanopore and 4bases collaborate on kit for BRCA1 and BRCA2 gene analysis

March 20, 2023
Medical Communications

Oxford Nanopore Technologies and Swiss company 4bases have announced a collaboration making 4bases kits with Oxford Nanopore’s sequencing technology. These …

News

NICE recommends OXLUMO®▼ (lumasiran) in England as first therapy to treat underlying cause of ultra-rare condition primary hyperoxaluria type 1 (PH1)

March 20, 2023
Business Services

MAIDENHEAD, UK, Monday 20th March 2023 – Alnylam UK Limited, the leading RNA interference (RNAi) therapeutics company, today welcomed a …

News
Press release

New data suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing

March 20, 2023
Business Services

STEVENAGE, UK, March 20, 2023 – New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in …

News
Press release

Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset

March 20, 2023
Business Services

Basel, March 20, 2023 — Novartis today presented new data which underscore the transformational and sustained benefit of Zolgensma® (onasemnogene abeparvovec), …

News
Press release

Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia

March 20, 2023
Business Services

Milan, Italy, March 20, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A.

News
Press release

Sun Pharma settles at $75m in industry-wide price-fixing case

March 17, 2023
Sales and Marketing

Sun Pharma has decided a settlement of $75m as part of a case surrounding various pharma companies fixing their prices. …

News

Sanofi to cut insulin prices by 78% starting January 2024

March 17, 2023
Sales and Marketing

French pharmaceutical company Sanofi has announced that it will cut the list price of its Lantus (insulin glargine injection) 100 …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026